424 related articles for article (PubMed ID: 17253590)
1. Effects of glucocorticoids on radiological progression in rheumatoid arthritis.
Kirwan JR; Bijlsma JW; Boers M; Shea BJ
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD006356. PubMed ID: 17253590
[TBL] [Abstract][Full Text] [Related]
2. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons.
Graudal N; Jürgens G
Arthritis Rheum; 2010 Oct; 62(10):2852-63. PubMed ID: 20560138
[TBL] [Abstract][Full Text] [Related]
3. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Ruiz Garcia V; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Bernal JA
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD007649. PubMed ID: 28884785
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Ruiz Garcia V; Jobanputra P; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Kynaston-Pearson FJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD007649. PubMed ID: 25231904
[TBL] [Abstract][Full Text] [Related]
5. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
Gotzsche PC; Johansen HK
Cochrane Database Syst Rev; 2002; (2):CD000189. PubMed ID: 12076385
[TBL] [Abstract][Full Text] [Related]
6. Moderate-term, low-dose corticosteroids for rheumatoid arthritis.
Criswell LA; Saag KG; Sems KM; Welch V; Shea B; Wells G; Suarez-Almazor ME
Cochrane Database Syst Rev; 2000; 1998(2):CD001158. PubMed ID: 10796420
[TBL] [Abstract][Full Text] [Related]
7. Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis.
Hilliquin S; Hugues B; Mitrovic S; Gossec L; Fautrel B
Ann Rheum Dis; 2018 Aug; 77(8):1099-1106. PubMed ID: 29884751
[TBL] [Abstract][Full Text] [Related]
8. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoid use in rheumatoid arthritis patients and the onset of pneumonia: a systematic review and meta-analysis.
Elsouri KN; Arboleda V; Basbous L; Heiser S; Collins DP; Ragusa P; Baxter C; Cabrera D; Akhand T; Stermer E; Sharma K; Seguro C; Hardigan P; Kesselman M; Beckler MD
J Osteopath Med; 2023 Apr; 123(4):179-186. PubMed ID: 36691851
[TBL] [Abstract][Full Text] [Related]
10. A dose of only 5 mg prednisolone daily retards radiographic progression in early rheumatoid arthritis - the Low-Dose Prednisolone Trial.
Wassenberg S; Rau R; Zeidler H;
Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S68-72. PubMed ID: 22018187
[TBL] [Abstract][Full Text] [Related]
11. Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis.
Guski LS; Jürgens G; Pedder H; Levinsen NKG; Andersen SE; Welton NJ; Graudal N
JAMA Netw Open; 2023 Oct; 6(10):e2335950. PubMed ID: 37801318
[TBL] [Abstract][Full Text] [Related]
12. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
Gotzsche PC; Johansen HK
Cochrane Database Syst Rev; 2001; (2):CD000189. PubMed ID: 11405954
[TBL] [Abstract][Full Text] [Related]
13. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
Gotzsche PC; Johansen HK
Cochrane Database Syst Rev; 2000; (2):CD000189. PubMed ID: 10796316
[TBL] [Abstract][Full Text] [Related]
14. [Use of glucocorticoids in rheumatoid arthritis].
Jacobsen S
Ugeskr Laeger; 2000 Feb; 162(6):770-2. PubMed ID: 10689949
[TBL] [Abstract][Full Text] [Related]
15. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.
van Everdingen AA; Jacobs JW; Siewertsz Van Reesema DR; Bijlsma JW
Ann Intern Med; 2002 Jan; 136(1):1-12. PubMed ID: 11777359
[TBL] [Abstract][Full Text] [Related]
16. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
Gotzsche PC; Johansen HK
Cochrane Database Syst Rev; 2003; (1):CD000189. PubMed ID: 12535392
[TBL] [Abstract][Full Text] [Related]
17. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
Gotzsche PC; Johansen HK
Cochrane Database Syst Rev; 2004; 2005(3):CD000189. PubMed ID: 15266426
[TBL] [Abstract][Full Text] [Related]
18. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study.
Hafström I; Albertsson K; Boonen A; van der Heijde D; Landewé R; Svensson B;
Ann Rheum Dis; 2009 Apr; 68(4):508-13. PubMed ID: 18420939
[TBL] [Abstract][Full Text] [Related]
19. Anakinra for rheumatoid arthritis.
Mertens M; Singh JA
Cochrane Database Syst Rev; 2009 Jan; (1):CD005121. PubMed ID: 19160248
[TBL] [Abstract][Full Text] [Related]
20. Penicillamine for treating rheumatoid arthritis.
Suarez-Almazor ME; Spooner C; Belseck E
Cochrane Database Syst Rev; 2000; (4):CD001460. PubMed ID: 11034719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
